Kerafast Partners with the National Cancer Institute (NCI) –
Enables Sharing of NCI Research Materials through Kerafast platform
Partnership seeks to advance scientific discovery by offering important bioreagents
Boston, Mass; Aug 19, 2015. Kerafast Inc., developers of an online platform to facilitate accessibility to unique bioresearch materials from academic and government laboratories across the globe, today announced an agreement to make important research materials from the National Cancer Institute available through Kerafast’s platform. With this agreement, Kerafast has now partnered with 122 institutes.
“Kerafast helps to facilitate a community of both Providing and Procuring laboratories that work towards the cure of disease by enabling access to rare and unique research reagents,” said Dr. Robert Bondaryk, Chief Executive Officer. “We are extremely honored to have the National Cancer Institute as the 122nd member of our program, and specifically to assist in offering these important reagents to the scientific community.”
Over the coming months, research materials from the National Cancer Institute will be added to Kerafast’s online catalog and made available via a straightforward research use only “click license.”
About Kerafast, Inc.
Since its founding in 2011, Kerafast has partnered with more than 120 prominent academic research institutions internationally that provide thousands of rare and unique ‘Reagents for the Greater Good’ for the benefit of the scientific community working toward the cure of disease in 48 countries on 6 continents. Visit kerafast.com for more information.
Jennifer M. Rossi, Ph.D.
Chief Operating Officer